Company intelligence / Profile preview

PROGEN

Heidelberg, Baden-Württemberg, Germanyprogen.co.kr ↗

Ownership: Public · 296160
Development stage: Phase 2

Overview

PROGEN GmbH specializes in high-quality antibodies, ELISAs including those targeting adeno-associated virus components critical to gene therapy research. It operates as a wholly owned subsidiary of R-Biopharm AG since 2012. The company supports global academic and industrial partners by providing validated analytical tools that facilitate safe advancement of novel therapies but does not itself develop drugs or have clinical-stage programs.

Modalities: Antibodies (including recombinant antibodies)ELISA kits for AAV titration and human antibody detectionAdeno-associated virus (AAV) analytical tools for gene therapy research
Industry: Protein Biomarker Diagnostics

Drug pipeline

3 assets

PG-102

Phase 2

Indications: Obesity, Type 2 diabetes mellitus

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on PROGEN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROGEN.

Explore the full profile